AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

Phase 3

Completed

Conditions: Moderate to Severe Asthma

Interventions: Drug: Tezepelumab
Drug: Placebo

First Posted Date: 2021-09-30

Last Posted Date: 2023-06-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 70

Registration Number: NCT05062759

Locations: 🇺🇸
Research Site, Milwaukee, Wisconsin, United States

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Ceralasertib
Biological: Durvalumab

First Posted Date: 2021-09-29

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 194

Registration Number: NCT05061134

Locations: 🇬🇧
Research Site, Northwood, United Kingdom

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Dato-DXd
Drug: AZD0171
Drug: Oleclumab
Drug: Monalizumab
Drug: Pemetrexed/Cisplatin
Drug: Carboplatin
Drug: Volrustomig
Drug: Pemetrexed/Carboplatin
Drug: Cisplatin
Drug: Rilvegostomig
Drug: Carboplatin/Paclitaxel

First Posted Date: 2021-09-29

Last Posted Date: 2025-05-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 630

Registration Number: NCT05061550

Locations: 🇹🇷
Research Site, Izmir, Turkey

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventions: Drug: Acalabrutinib
Drug: Venetoclax
Drug: Obinutuzumab

First Posted Date: 2021-09-27

Last Posted Date: 2025-03-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 607

Registration Number: NCT05057494

Locations: 🇪🇸
Research Site, Palma de Mallorca, Spain

A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

Phase 4

Terminated

Conditions: COVID-19, SARS-CoV-2

Interventions: Biological: AZD1222

First Posted Date: 2021-09-27

Last Posted Date: 2025-01-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 34

Registration Number: NCT05057897

Locations: 🇺🇦
Research Site, Kharkiv, Ukraine

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Phase 3

Terminated

Conditions: Renal Insufficiency, Chronic
Hyperkalemia

Interventions: Drug: Sodium Zirconium Cyclosilicate (SZC)
Drug: Placebo
Drug: Lisinopril
Drug: Valsartan
Drug: Irbesartan

First Posted Date: 2021-09-24

Last Posted Date: 2025-02-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 716

Registration Number: NCT05056727

Locations: 🇻🇳
Research Site, Hue, Vietnam

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AZD4831
Drug: Midazolam

First Posted Date: 2021-09-22

Last Posted Date: 2021-12-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 14

Registration Number: NCT05052710

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England

Completed

Conditions: Covid-19 Infection

First Posted Date: 2021-09-17

Last Posted Date: 2023-11-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 18373714

Registration Number: NCT05047822

Locations: 🇬🇧
Research Site, Leeds, United Kingdom

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Trastuzumab Deruxtecan
Drug: Cisplatin
Drug: Carboplatin
Drug: Pembrolizumab
Drug: Pemetrexed

First Posted Date: 2021-09-17

Last Posted Date: 2025-04-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 450

Registration Number: NCT05048797

Locations: 🇹🇷
Research Site, Çankaya, Turkey

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Phase 3

Active, not recruiting

Conditions: Papillary Renal Cell Carcinoma

Interventions: Drug: savolitinib
Drug: sunitinib
Drug: durvalumab

First Posted Date: 2021-09-13

Last Posted Date: 2025-05-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 148

Registration Number: NCT05043090

Locations: 🇬🇧
Research Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy